Compare LXFR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | ALT |
|---|---|---|
| Founded | 1898 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.4M | 421.5M |
| IPO Year | 2002 | 2005 |
| Metric | LXFR | ALT |
|---|---|---|
| Price | $14.11 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 101.2K | ★ 4.2M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $384,600,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | $47.43 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.53 | $2.73 |
| 52 Week High | $16.03 | $7.73 |
| Indicator | LXFR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 28.55 |
| Support Level | $12.29 | N/A |
| Resistance Level | $14.83 | $4.25 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | 0.12 | -0.06 |
| Stochastic Oscillator | 75.61 | 3.37 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.